Acceptance of Self-Sampling by Women Not Regularly Participating in Cervical Cancer Screening in Areas with Low Medical Density: A Qualitative Study within the French CapU4 Trial

Author:

Le Goff Johane1,Le Duc-Banaszuk Anne-Sophie2ORCID,Lefeuvre Caroline3ORCID,Pivert Adeline3,Ducancelle Alexandra3,De Pauw Hélène4ORCID,Arbyn Marc45ORCID,Vinay Aubeline1,Rexand-Galais Franck1ORCID

Affiliation:

1. University of Angers, CLiPsy, SFR CONFLUENCES, F-49000 Angers, France

2. Pays de la Loire Regional Cancer Screening Coordination Center (CRCDC Pays de La Loire), F-49000 Angers, France

3. University of Angers, CHU Angers, HIFIH, SFR ICAT, F-49000 Angers, France

4. Unit Cancer Epidemiology, Belgian Cancer Center, Sciensano, B1050 Brussels, Belgium

5. Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, Ghent University, B9000 Ghent, Belgium

Abstract

Cervical cancer (CC) was diagnosed in 3159 women in France in 2023, and 1117 died from it. Organized screening for cervical cancer is potentially very effective for participating women. However, reaching under-screened populations remains a major challenge. The present qualitative study explored women’s opinions on what discourages or encourages them to participate in CC screening and assessed the acceptability of two experimental strategies (urinary or vaginal self-sampling kits) to increase the screening coverage in three rural French administrative departments with low medical density and/or low screening participation rates. Forty-eight semi-structured interviews and four focus groups were conducted by a team of psychologists. Results showed that the participants accepted at-home self-sampling to reach non-participating women in medically underserved areas. However, they suggested that the type of kit sent should be adapted to the patient’s profile (embarrassment from earlier exams, cultural aspects, fear of invasiveness, etc.), and that kits should be simple to use (in understandable language taking sociocultural aspects into account). Women wished to be assured that testing on self-samples is accurate and needed information about further actions in case of a positive result.

Funder

the French National Cancer Institute

the Horizon 2020 Framework Programme for Research and Innovation of the European Commission, through the RISCC Network

Publisher

MDPI AG

Reference57 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J. Clin.,2021

2. World Health Organization (2024, May 07). Papillomavirus Humain et Cancer. Available online: https://www.who.int/fr/news-room/fact-sheets/detail/human-papilloma-virus-and-cancer.

3. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer;Arbyn;Vaccine,2012

4. WHO launches strategy to accelerate elimination of cervical cancer;Das;Lancet Oncol.,2021

5. Global estimates of incidence and mortality of cervical cancer in 2020: A baseline analysis of the WHO Global Cervical Cancer Elimination Initiative;Singh;Lancet Glob. Health,2023

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3